IO101 is a peptide vaccine encompassing an HLA-A2-restricted, 9 amino acid IDO-derived CD8+ T-cell epitope. IO101 was the basis for the discovery of IO102, a anti-cancer therapy containing a 21-mer IDO-derived peptide.

A first-in-man clinical phase I vaccination trial using IO101 was conducted. The study comprised 15 HLA-A2+ patients with advanced NSCLC who were vaccinated with IO101 in Montanide adjuvant following pre-treatment with topical Imiquimod (Aldara® Cream). The vaccine was well tolerated with manageable side effects and no CTCAE grade 3/4 toxicities.

One patient obtained an objective partial response after demonstrating continuous regression of liver metastases on vaccine treatment for 1 year.

Presently a small phase II study is ongoing in melanoma patients. In this study, IO101 together with an A2 Survivin peptide is used for vaccination in combination with temozolomide chemotherapy treatment.

Publications by founders

Cytotherapy, August 2016: Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab